Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving chemotherapy and monoclonal antibody therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying donor stem cell transplant in treating patients with mantle cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Research UK
• Treatments: Alemtuzumab; Carmustine; Cytarabine; Etoposide; Melphalan

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of mantle cell lymphoma

• No relapsed or progressive disease

• Achieved at least a partial remission following induction chemotherapy

• HLA-matched donor available

• Blood samples from both patient and donor available for chimerism studies

• No central nervous system involvement

PATIENT CHARACTERISTICS:

• ECOG performance status 2-4

• Considered fit for transplant by treating physician

• Serum bilirubin ≤ 1.5 times upper limit of normal

• Alkaline phosphatase ≤ 2 times normal

• Creatinine clearance ≥ 50 mL/min

• Ejection fraction > 50% (no inadequate cardiac function)

• Not pregnant or nursing

• Negative pregnancy test

• No symptomatic respiratory compromise

• No serious concurrent disease which would preclude allograft

• No known serological positivity for hepatitis B, hepatitis C, or HIV

• No history of a psychological illness or condition that would affect compliance

• No previous malignancy within the past 5 years except nonmelanoma skin tumors or stage 0 (in situ) cervical carcinoma

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics